Stamatatos Leonidas, Pancera Marie, McGuire Andrew T
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Global Health, University of Washington, Seattle, WA, USA.
Immunol Rev. 2017 Jan;275(1):203-216. doi: 10.1111/imr.12483.
In 2009, Dimitrov's group reported that the inferred germline (iGL) forms of several HIV-1 broadly neutralizing antibodies (bNAbs) did not display measurable binding to a recombinant gp140 Env protein (derived from the dual-tropic 89.6 virus), which was efficiently recognized by the mature (somatically mutated) antibodies. At that time, a small number of bNAbs were available, but in the following years, the implementation of high-throughput B-cell isolation and sequencing assays and of screening methodologies facilitated the isolation of greater numbers of bNAbs from infected subjects. Using these newest bNAbs, and a wide range of diverse recombinant Envs, we and others confirmed the observations made by Dimitrov's group. The results from these studies created a paradigm shift in our collective thinking as to why recombinant Envs are ineffective in eliciting bNAbs and has led to the "germline-targeting" immunization approach. Here we discuss this approach in detail: what has been done so far, the advantages and limitations of the current germline-targeting immunogens and of the animal models used to test them, and we conclude with a few thoughts about future directions in this area of research.
2009年,季米特洛夫团队报告称,几种HIV-1广谱中和抗体(bNAbs)的推断种系(iGL)形式对重组gp140 Env蛋白(源自双嗜性89.6病毒)未表现出可检测到的结合,而成熟(体细胞突变)抗体能有效识别该蛋白。当时,仅有少数几种bNAbs,但在随后几年中,高通量B细胞分离和测序检测以及筛选方法的应用,促进了从感染个体中分离出更多的bNAbs。利用这些最新的bNAbs以及多种不同的重组Env,我们和其他研究人员证实了季米特洛夫团队的观察结果。这些研究结果使我们对于重组Env为何无法有效引发bNAbs的总体认识发生了范式转变,并催生了“靶向种系”免疫方法。在此,我们详细讨论这种方法:目前已开展的工作、当前靶向种系免疫原及用于测试它们的动物模型的优缺点,最后我们对该研究领域的未来方向提出几点思考。